ReviewCurrent obesity reports2023
The Fat Kidney.
Review in Current obesity reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- A Dynamic Online Nomogram for Predicting Postoperative Acute Kidney Injury After Sleeve Gastrectomy.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Obesity and Its Clinical Implications in End-Stage Kidney Disease.Medicina (Kaunas, Lithuania) · 2026Review
- Beneficial Impact of Kaempferol on Kidney Function and Long-Term Prognosis in Overweight or Obese Adults.Food science & nutrition · 2026Article
- Longitudinal Impacts of Bariatric Surgery on eGFR in CKD Patients.American journal of nephrology · 2026Article
- Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.EXCLI journal · 2026Article
- Renal Function in Patients after Metabolic and Bariatric Surgery.Obesity surgery · 2025Article
- Obesity and its management in primary care setting.Journal of diabetes and its complications · 2025Review
- Advancing Obesity Management: the Very Low-Energy Ketogenic therapy (VLEKT) as an Evolution of the "Traditional" Ketogenic Diet.Current obesity reports · 2025Review
- Emerging insights into the role of visceral adipose tissue in diabetic kidney disease.Frontiers in nutrition · 2025Review
- Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.Frontiers in cardiovascular medicine · 2025Review
- Article
- From Adipose to Ailing Kidneys: The Role of Lipid Metabolism in Obesity-Related Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Review
- The Kidney in Obesity: Current Evidence, Perspectives and Controversies.Current obesity reports · 2024Review
- Changes in glomerular filtration rate in patients with body mass index ≥35 kg/mObesity science & practice · 2024Article
- Bariatric surgery and the diseased kidney: a 5-year assessment of safety and postoperative renal outcomes.Surgical endoscopy · 2024Article
- Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD).Journal of clinical & translational endocrinology · 2024Review
- Association of Body Composition-Related Indicators with Urinary Protein Levels and Proteinuria Remission in Patients with Primary Membranous Nephropathy.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to summarize the current evidence on the role of obesity in the development and progression of chronic kidney disease and the current evidence on nutritional, pharmacological, and surgical strategies for the management of individuals with obesity and chronic kidney disease. RECENT
findingsObesity can hurt the kidney via direct pathways, through the production of pro-inflammatory adipocytokines, and indirectly due to systemic complications of obesity, including type 2 diabetes mellitus and hypertension. In particular, obesity can damage the kidney through alterations in renal hemodynamics resulting in glomerular hyperfiltration, proteinuria and, finally, impairment in glomerular filtratation rate. Several strategies are available for weight loss and maintenance, such as the modification of lifestyle (diet and physical activity), anti-obesity drugs, and surgery therapy, but there are no clinical practice guidelines to manage subjects with obesity and chronic kidney disease. Obesity is an independent risk factor for the progression of chronic kidney disease. In subjects with obesity, weight loss can slow down the progression of renal failure with a significant reduction in proteinuria and improvement in glomerular filtratation rate. Specifically, in the management of subjects with obesity and chronic renal disease, it has been shown that bariatric surgery can prevent the decline in renal function, while further clinical studies are needed to evaluate the efficacy and safety on the kidney of weight reducing agents and the very low-calorie ketogenic diet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.